RxDoctor Payments Data

Katelynn Dougherty Soper

Family · Glen Burnie, MDNPI 1083387369

Payments from drug & device makers

$1,770in general payments, 2019–2025

Across 44 payments — averaging $40.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$951
  • GSK$148
  • Pharmaessentia USA Corporation$116
  • AbbVie$109
  • Astellas Pharma US Inc$88
  • Gilead$49
  • plus $309 from 11 others

What the payments were for

  • Food & beverage$76843%
  • Education$1056%
  • Other$89751%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,770 in reported general payments places this provider in the 80th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$50,430
Medicare patients
152
Services billed
1,424

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NubeqaDarolutamide16$221,530
ImbruvicaIbrutinib18$218,007
Lenalidomide15$216,721
CalquenceAcalabrutinib Maleate14$153,913
EliquisApixaban40$50,313
Imatinib Mesylate14$23,884
XareltoRivaroxaban15$20,138
CreonLipase/Protease/Amylase12$11,399
Anastrozole39$1,288
Letrozole32$1,169
Oxycodone Hcl67$820
Ondansetron Hcl24$705
Potassium Chloride35$695
ValacyclovirValacyclovir Hcl19$643
Prochlorperazine Maleate32$609

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence$29$153,91314 claims
PfizerEliquis$38$50,31340 claims
Johnson & JohnsonXarelto$33$20,13815 claims
AbbVieCreon$109$11,39912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,843 family providers in Maryland.

Other family in Glen Burnie

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →